Perspective Therapeutics (CATX) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Perspective Therapeutics (CATX) over the past year, losing 17.0% versus a loss of 29.8%. Over five years, CATX leads with a -56.3% price change compared with -75.4% for VNDA. Perspective Therapeutics is the larger company by market cap ($309.4 million vs $273.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | VNDA |
|---|---|---|
| Share price | $2.71 | $4.53 |
| Market cap | $309.35M | $273.90M |
| 1-day change | +10.16% | -0.66% |
| YTD return | -1.45% | -48.64% |
| 1-year return | -29.79% | -17.03% |
| 5-year return | -56.29% | -75.39% |
| Forward P/E | — | 22.65 |
| EPS (TTM) | $-1.33 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $9.94 |
| 52-week low | $1.96 | $4.27 |
| Distance from 52-week high | -56.01% | -54.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +353.51% | +159.38% |
| Average volume | 1.67M | 974.13K |
| Shares outstanding | 114.15M | 60.46M |
| Employees | 163 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed CATX by 12.8 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
CATX vs VNDA FAQ
Which is bigger, Perspective Therapeutics or Vanda Pharmaceuticals?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $309.35M compared with $273.90M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, CATX or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -29.79% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.